Does Soluble TREM2 Protect Against Alzheimer's Disease?

Triggering Receptor Expressed in Myeloid Cells 2 (TREM2) is a pattern recognition receptor on myeloid cells, and is upregulated on microglia surrounding amyloid plaques in Alzheimer's disease (AD). Rare, heterozygous mutations in TREM2 (e.g., R47H) increase AD risk several fold. TREM2 can be cl...

Full description

Bibliographic Details
Main Authors: Guy C. Brown, Peter St George-Hyslop
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Aging Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fnagi.2021.834697/full
_version_ 1798024882398691328
author Guy C. Brown
Peter St George-Hyslop
Peter St George-Hyslop
author_facet Guy C. Brown
Peter St George-Hyslop
Peter St George-Hyslop
author_sort Guy C. Brown
collection DOAJ
description Triggering Receptor Expressed in Myeloid Cells 2 (TREM2) is a pattern recognition receptor on myeloid cells, and is upregulated on microglia surrounding amyloid plaques in Alzheimer's disease (AD). Rare, heterozygous mutations in TREM2 (e.g., R47H) increase AD risk several fold. TREM2 can be cleaved at the plasma membrane by metalloproteases to release the ectodomain as soluble TREM2 (sTREM2). Wild-type sTREM2 binds oligomeric amyloid beta (Aβ) and acts as an extracellular chaperone, blocking and reversing Aβ oligomerization and fibrillization, and preventing Aβ-induced neuronal loss in vitro. Whereas, R47H sTREM2 increases Aβ fibrillization and neurotoxicity. AD brains expressing R47H TREM2 have more fibrous plaques with more neuritic pathology around these plaques, consistent with R47H sTREM2 promoting Aβ fibrillization relative to WT sTREM2. Brain expression or injection of wild-type sTREM2 reduces pathology in amyloid models of AD in mice, indicating that wild-type sTREM2 is protective against amyloid pathology. Levels of sTREM2 in cerebrospinal fluid (CSF) fall prior to AD, rise in early AD, and fall again in late AD. People with higher sTREM2 levels in CSF progress more slowly into and through AD than do people with lower sTREM2 levels, suggesting that sTREM2 protects against AD. However, some of these experiments can be interpreted as full-length TREM2 protecting rather than sTREM2, and to distinguish between these two possibilities, we need more experiments testing whether sTREM2 itself protects in AD and AD models, and at what stage of disease. If sTREM2 is protective, then treatments could be designed to elevate sTREM2 in AD.
first_indexed 2024-04-11T18:09:46Z
format Article
id doaj.art-7cc45101dffe4ce69d803f10df62d3fc
institution Directory Open Access Journal
issn 1663-4365
language English
last_indexed 2024-04-11T18:09:46Z
publishDate 2022-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Aging Neuroscience
spelling doaj.art-7cc45101dffe4ce69d803f10df62d3fc2022-12-22T04:10:11ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652022-01-011310.3389/fnagi.2021.834697834697Does Soluble TREM2 Protect Against Alzheimer's Disease?Guy C. Brown0Peter St George-Hyslop1Peter St George-Hyslop2Department of Biochemistry, University of Cambridge, Cambridge, United KingdomDepartment of Medicine, University of Cambridge, Cambridge, United KingdomDepartment of Medicine, University of Toronto, Toronto, ON, CanadaTriggering Receptor Expressed in Myeloid Cells 2 (TREM2) is a pattern recognition receptor on myeloid cells, and is upregulated on microglia surrounding amyloid plaques in Alzheimer's disease (AD). Rare, heterozygous mutations in TREM2 (e.g., R47H) increase AD risk several fold. TREM2 can be cleaved at the plasma membrane by metalloproteases to release the ectodomain as soluble TREM2 (sTREM2). Wild-type sTREM2 binds oligomeric amyloid beta (Aβ) and acts as an extracellular chaperone, blocking and reversing Aβ oligomerization and fibrillization, and preventing Aβ-induced neuronal loss in vitro. Whereas, R47H sTREM2 increases Aβ fibrillization and neurotoxicity. AD brains expressing R47H TREM2 have more fibrous plaques with more neuritic pathology around these plaques, consistent with R47H sTREM2 promoting Aβ fibrillization relative to WT sTREM2. Brain expression or injection of wild-type sTREM2 reduces pathology in amyloid models of AD in mice, indicating that wild-type sTREM2 is protective against amyloid pathology. Levels of sTREM2 in cerebrospinal fluid (CSF) fall prior to AD, rise in early AD, and fall again in late AD. People with higher sTREM2 levels in CSF progress more slowly into and through AD than do people with lower sTREM2 levels, suggesting that sTREM2 protects against AD. However, some of these experiments can be interpreted as full-length TREM2 protecting rather than sTREM2, and to distinguish between these two possibilities, we need more experiments testing whether sTREM2 itself protects in AD and AD models, and at what stage of disease. If sTREM2 is protective, then treatments could be designed to elevate sTREM2 in AD.https://www.frontiersin.org/articles/10.3389/fnagi.2021.834697/fullTREM2sTREM2microgliaAlzheimer's diseaseamyloid betaneuroinflammation
spellingShingle Guy C. Brown
Peter St George-Hyslop
Peter St George-Hyslop
Does Soluble TREM2 Protect Against Alzheimer's Disease?
Frontiers in Aging Neuroscience
TREM2
sTREM2
microglia
Alzheimer's disease
amyloid beta
neuroinflammation
title Does Soluble TREM2 Protect Against Alzheimer's Disease?
title_full Does Soluble TREM2 Protect Against Alzheimer's Disease?
title_fullStr Does Soluble TREM2 Protect Against Alzheimer's Disease?
title_full_unstemmed Does Soluble TREM2 Protect Against Alzheimer's Disease?
title_short Does Soluble TREM2 Protect Against Alzheimer's Disease?
title_sort does soluble trem2 protect against alzheimer s disease
topic TREM2
sTREM2
microglia
Alzheimer's disease
amyloid beta
neuroinflammation
url https://www.frontiersin.org/articles/10.3389/fnagi.2021.834697/full
work_keys_str_mv AT guycbrown doessolubletrem2protectagainstalzheimersdisease
AT peterstgeorgehyslop doessolubletrem2protectagainstalzheimersdisease
AT peterstgeorgehyslop doessolubletrem2protectagainstalzheimersdisease